甲状腺髓样癌中治疗靶点SEZ6的检测
本研究在78例甲状腺髓样癌(MTC)中检测SEZ6免疫表达,并与临床病理特征、结局及分子谱进行关联分析。结果显示,SEZ6在原发灶中阳性率为91%至93%,在区域复发灶中为100%,在远处转移灶中为75%至83%;高表达与男性、晚期及甲状腺外侵犯相关。SEZ6与结局及RET/RAS突变状态无相关性。
要点
- SEZ6在原发MTC中免疫阳性率为91%至93%,区域复发灶为100%,远处转移灶为75%至83%。
- SEZ6高表达与男性、晚期及甲状腺外侵犯相关,但与结局及RET/RAS突变状态无关。
- 无RET/RAS突变的MTC中SEZ6阳性频率为83%,提示SEZ6靶向抗体偶联药物或可成为有前景的靶向治疗。
核心结论
- SEZ6可能作为MTC的新型生物标志物。
- SEZ6在MTC中缺乏预后价值,但其在91%至93%的MTC(包括无RET和RAS突变的MTC)中呈阳性,使SEZ6靶向抗体偶联药物治疗成为MTC有前景的靶向治疗。
研究设计与样本
- 在78例MTC中研究SEZ6免疫表达,并与临床病理特征、结局及分子谱进行关联分析。
- 使用两种不同的SEZ6抗体克隆SC17.14和14E5检测SEZ6免疫阳性。
主要发现
- 使用SC17.14和14E5两种抗体克隆,SEZ6免疫阳性见于91%至93%的原发MTC、100%的区域复发灶和75%至83%的远处转移灶。
- 使用H评分判定的SEZ6高免疫表达与男性、晚期及甲状腺外侵犯相关。
- SEZ6表达与MTC结局或RET/RAS突变状态无相关性。
- 无RET/RAS突变的MTC中SEZ6阳性频率为83%。
关键数值与推荐
- 原发MTC中SEZ6免疫阳性率为91%至93%。
- 区域复发灶中SEZ6免疫阳性率为100%。
- 远处转移灶中SEZ6免疫阳性率为75%至83%。
- 无RET/RAS突变的MTC中SEZ6阳性频率为83%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Seizure-related 6 homolog (SEZ6) is a cDNA that is strongly associated with neuroendocrine differentiation. Recently, SEZ6 expression was found in a subset of small cell lung carcinoma (SCLC). Furthermore, ABBV-011, a novel antibody-drug conjugate targeting SEZ6 has been developed and is currently in a clinical trial for the treatment of SCLC and neuroendocrine neoplasms, including medullary thyroid carcinoma (MTC). OBJECTIVE: We herein present the first evidence that SEZ6 is highly expressed in MTC. METHODS: SEZ6 immuno-expression was studied in 78 MTCs and correlated with clinicopathologic characteristics, outcome, and molecular profile. RESULTS: SEZ6 was highly expressed in primary tumors, regional recurrence, and distant metastasis. Using 2 different SEZ6 antibody clones, SC17.14 and 14E5, SEZ6 immunopositivity was seen in 91% to 93% of primary MTCs, 100% of regional recurrence, and 75% to 83% of distant metastasis. High level of SEZ6 immuno-expression determined using H score was associated with male sex, advanced stage, and extrathyroidal thyroidal extension. There was no correlation between SEZ6 expression and outcome or RET/RAS mutation status in MTC. The frequency of SEZ6 positivity in MTC without RET/RAS mutations was 83%. CONCLUSION: SEZ6 may serve as a novel biomarker for MTCs. Although SEZ6 lacks any prognostic values in MTC, its positivity in 91% to 93% of MTCs, including MTCs without RET and RAS mutations, renders SEZ6-targeted antibody-drug conjugate therapy a promising targeted therapy for MTCs.
引用
- Xu B, Baine MK, Jungbluth A, et al. Detection of SEZ6, a Therapeutic Target, in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2025. PMID: 39324657. doi:10.1210/clinem/dgae672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。